{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:09:32Z","timestamp":1790816972527,"version":"4.1.0"},"reference-count":21,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The multicenter, open-label, randomized phase 2 NCI-9944 study ( NCT02595892 ) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank P = .044, which met the one-sided significance level of 0.1 used for sample size calculation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We report here the final overall survival (OS) analysis and biomarker correlations (ATM expression by immunohistochemistry, mutational signature 3 and a genomic biomarker of replication stress) along with post-hoc exploratory analyses to adjust for crossover from gemcitabine to gemcitabine\/berzosertib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At the data cutoff of January 27, 2023 (&gt;30 months of additional follow-up from the primary analysis), median OS was 59.4 weeks with gemcitabine\/berzosertib versus 43.0 weeks with gemcitabine alone (HR 0.79, 90% CI 0.52 to 1.2, one-sided log-rank P = .18). An OS benefit with addition of berzosertib to gemcitabine was suggested in patients stratified into the platinum-free interval \u22643 months (N = 26) subgroup (HR, 0.48, 90% CI 0.22 to 1.01, one-sided log-rank P =.04) and in patients with ATM-negative\/low (N = 24) tumors (HR, 0.50, 90% CI 0.23 to 1.08, one-sided log-rank P = .06).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The results of this follow-up analysis continue to support the promise of combined gemcitabine\/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po.23.00635","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:59:32Z","timestamp":1713455972000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":24,"title":["Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-1479","authenticated-orcid":true,"given":"Panagiotis A.","family":"Konstantinopoulos","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Chun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-7853","authenticated-orcid":true,"given":"Elizabeth K.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-0105","authenticated-orcid":true,"given":"Alexandre Andr\u00e9 B.A.","family":"da Costa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-0549","authenticated-orcid":true,"given":"Doga","family":"Gulhan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics and Ludwig Center at Harvard, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-7104","authenticated-orcid":true,"given":"Andrea E.","family":"Wahner Hendrickson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8929-3070","authenticated-orcid":true,"given":"Bose","family":"Kochupurakkal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-6525","authenticated-orcid":true,"given":"David L.","family":"Kolin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-3972","authenticated-orcid":true,"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-8588","authenticated-orcid":true,"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-3216","authenticated-orcid":true,"given":"Elizabeth H.","family":"Stover","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Curtis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Sawyer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-3845","authenticated-orcid":true,"given":"Madeline","family":"Polak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanjan","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6294","authenticated-orcid":true,"given":"Alan D.","family":"D'Andrea","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniina","family":"F\u00e4rkkil\u00e4","sequence":"additional","affiliation":[{"name":"Research Program in Systems Oncology, FIMM and HiLife, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":true,"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-6992","authenticated-orcid":true,"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6606"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.0787"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6735"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00558-5"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30180-7"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25904-w"},{"key":"b9","first-page":"1","volume":"43","author":"van der Wal WM","year":"2011","journal-title":"J Stat Softw"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00617-9"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1038\/nature14184"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15315-8"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0390-2"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1602"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6455"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00139-5"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.573"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5580"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015214"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.23.00635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:59:50Z","timestamp":1713455990000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.23.00635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1200\/PO.23.00635"],"URL":"https:\/\/doi.org\/10.1200\/po.23.00635","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2300635"}}